TD Cowen analyst Ryan Langston maintains $Acadia Healthcare (ACHC.US)$ with a buy rating, and adjusts the target price from $70 to $66.
According to TipRanks data, the analyst has a success rate of 35.0% and a total average return of -6.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Acadia Healthcare (ACHC.US)$'s main analysts recently are as follows:
The firm lowered forward annual EBITDA estimates by 4%, largely to account for additional denovo startup costs and anticipated incremental costs associated with compliance and ramping of new facilities.
The stock could see a significant upward movement during 2025 as investor perception solidifies regarding the anticipated EBITDA acceleration in 2026. Analysts note that the company's 2026 EBITDA could see gains from the maturation of bed additions during 2024-2025 and declining startup costs. It is predicted that the company's valuation might normalize during 2025 as previous negative press diminishes and focus intensifies on the expected financial performance in 2026.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Ryan Langston維持$阿卡迪亞醫療保健 (ACHC.US)$買入評級，並將目標價從70美元下調至66美元。
根據TipRanks數據顯示，該分析師近一年總勝率為35.0%，總平均回報率為-6.1%。
此外，綜合報道，$阿卡迪亞醫療保健 (ACHC.US)$近期主要分析師觀點如下：
該公司將年度息稅折舊攤銷前利潤估計值下調了4％，這主要是由於denovo的額外啓動成本以及與合規和擴建新設施相關的預期增量成本。
隨着投資者對2026年預計息稅折舊攤銷前利潤加速的看法得到鞏固，該股在2025年可能會出現大幅上漲。分析師指出，該公司2026年的息稅折舊攤銷前利潤可能會因2024-2025年增加牀位的成熟和啓動成本的下降而獲得收益。預計隨着先前的負面新聞減少以及對2026年預期財務業績的關注加劇，該公司的估值可能會在2025年恢復正常。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
